At a Glance
| Oxytocin | Substance P | |
|---|---|---|
| Class | Neuropeptide | Neuropeptide, Pain mediator, Stress mediator |
| Routes | Intranasal | |
| Effects | 6 documented | 9 documented |
Dosage
Only in Oxytocin
intranasal
| Level | Dose |
|---|---|
| Light | 10–20 IU |
| Common | 20–40 |
Oxytocin, a Neuropeptide, and Substance P, a Neuropeptide, Pain mediator, Stress mediator, are frequently compared by users looking to understand their relative effects, dosage profiles, and safety considerations. Oxytocin is classified as a Neuropeptide while Substance P is a Neuropeptide, Pain mediator, Stress mediator, meaning they approach altered states through different pharmacological mechanisms. They share 1 documented effects in common, with 5 effects unique to Oxytocin and 8 unique to Substance P. This side-by-side comparison covers dosage, duration, subjective effects, and safety to help you make informed decisions.
| Oxytocin | Substance P | |
|---|---|---|
| Class | Neuropeptide | Neuropeptide, Pain mediator, Stress mediator |
| Routes | Intranasal | |
| Effects | 6 documented | 9 documented |
| Level | Dose |
|---|---|
| Light | 10–20 IU |
| Common | 20–40 |
| Strong | 40–60 IU |
No direct interaction data available between these substances. This does not mean the combination is safe.
No dangerous interactions recorded.
No dangerous interactions recorded.